Phase III success rate
Jul 11, 2016 23:12:37 GMT
via Tapatalk
investobefree22 and tomsylver like this
Post by stcks on Jul 11, 2016 23:12:37 GMT
I know nothing about this company. Just saw that they reported the phase III and it was not good.
From the sounds of it this is one of the 42% of drugs that do not make it after starting phase III testing. Something that we all need to keep in mind when involved in Biotechs. High rewards come with high losses.
This is the main reason I invent in Dr. Frost and not companies or drugs. How would he be buying the way he does if he did not believe that OPKO was going to be successful.
From the sound of it this was the company's only drug.
Article:
Cytrx phase III with aldoxorubicin misses primary endpoint in STS, post-clinical hold analysis to come
Share
By Randy Osborne, Staff Writer
A two-month clinical hold placed on the trial in late 2014 apparently skewed the much-awaited data from Cytrx Corp. from the phase III experiment comparing aldoxorubicin to investigator’s-choice therapy in patients with relapsed or refractory soft tissue sarcomas (STS), and the results available so far show a miss on the primary endpoint of progression-free survival (PFS).
From the sounds of it this is one of the 42% of drugs that do not make it after starting phase III testing. Something that we all need to keep in mind when involved in Biotechs. High rewards come with high losses.
This is the main reason I invent in Dr. Frost and not companies or drugs. How would he be buying the way he does if he did not believe that OPKO was going to be successful.
From the sound of it this was the company's only drug.
Article:
Cytrx phase III with aldoxorubicin misses primary endpoint in STS, post-clinical hold analysis to come
Share
By Randy Osborne, Staff Writer
A two-month clinical hold placed on the trial in late 2014 apparently skewed the much-awaited data from Cytrx Corp. from the phase III experiment comparing aldoxorubicin to investigator’s-choice therapy in patients with relapsed or refractory soft tissue sarcomas (STS), and the results available so far show a miss on the primary endpoint of progression-free survival (PFS).